Exclusive Negotiation Rights and Joint Development of an RECQL1-siRNA Nucleic Acid Drug
A program to obtain exclusive negotiation rights to consider acquiring rights in the future to GeneCare Research Institute’s RECQL1-siRNA and related technologies, and to advance joint development and animal studies.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.